Submit Manuscripts
Author Information
Subscribe/Renew
Email Alerts
Feedback
RSS Feed

About the Journal
Editorial Board & Staff

Interventions Homepage Imaging Homepage Interventions Homepage Imaging Homepage

ACC.org
Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions

ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction

ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease
cardiology careers collections past issues search home
     

J Am Coll Cardiol, 2007; 49:1272-1278, doi:10.1016/j.jacc.2007.02.025
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Trial Investigators
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patti, G.
Right arrow Articles by Di Sciascio, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patti, G.
Right arrow Articles by Di Sciascio, G.

Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention

Results of the ARMYDA-ACS Randomized Trial

Giuseppe Patti, MD, FACC*, Vincenzo Pasceri, MD, PhD, FACC{dagger}, Giuseppe Colonna, MD{ddagger}, Marco Miglionico, MD*, Dionigi Fischetti, MD{ddagger}, Gennaro Sardella, MD, FACC§, Antonio Montinaro, MD{ddagger} and Germano Di Sciascio, MD, FACC, FESC*,*

* Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy
{dagger} Interventional Cardiology Unit, San Filippo Neri Hospital, Rome, Italy
{ddagger} Interventional Cardiology Unit, Vito Fazzi Hospital, Lecce, Italy
§ Department of Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy.


Figure 1
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1 Study Design of the ARMYDA-ACS Trial

ARMYDA-ACS = Atorvastatin for Reduction of MYocardial Damage During Angioplasty—Acute Coronary Syndromes; CK-MB = creatine kinase-MB; CRP = C-reactive protein; MI = myocardial infarction; NSTE-ACS = non–ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; TVR = target vessel revascularization.

 

Figure 2
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2 ARMYDA-ACS Survival Curves

Actuarial curves of 30-day major adverse cardiac event (MACE)-free survival in the 2 arms. PCI = percutaneous coronary intervention.

 

Figure 3
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3 ARMYDA-ACS: Cardiac Marker Elevations

Incidence of postprocedural increase of creatine kinase-MB and troponin-I 1 to 3 times and >3 times above the upper limits of normal.

 

Figure 4
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4 ARMYDA-ACS: Odds Ratios for 30-Day MACE

Results of multivariable analysis showing 88% major adverse cardiac event (MACE) risk reduction at 30 days with atorvastatin (odds ratio 0.12, 95% confidence interval 0.05 to 0.50; p = 0.004). ACE = angiotensin-converting enzyme; LVEF = left ventricular ejection fraction; NSTEMI = non–ST-segment elevation myocardial infarction.

 
 
  cardiology careers collections past issues search home